All News

Creating a medical family tree is helpful. If cancer is common, noting which branches include it can help inform decisions.

Getting a job while having health issues can be a problem, but don't just take my word for it.

When dealing with cancer, it's important to know your limits and be OK with them, to focus on the good.

Vassiliki A. Papadimitrakopoulou, M.D., honored at the 19th Annual International Lung Cancer Congress.

They say when you begin to help others, you reach a deeper state of healing.

Sometimes life throws you the curveball of cancer.

Researchers are on the hunt for a better biomarker in ovarian cancer that could detect the disease in earlier stages.

The increase in health insurance deductibles has affected health care for many cancer patients. These changes contribute to unnecessary stress in the lives of some affected by breast cancer. Read one survivor's viewpoint.

We as cancer patients need to be involved in our own medical care and to advocate for ourselves and for each other.

Dr. Inga Hofman Zhang from the University of Wisconsin School of Medicine provides an update on treating MDS in children.

Dr. Naval Daver from MD Anderson Cancer Center talks about the relationship between MDS and AML and discusses new and novel treatments for both diseases.

Dr. Antonio Risitano, a hematologist from the Univeristy of Naples, discusses the most current thinking on PNH and its treatment. Questions answered include:

Dr. Eric Padrone, a hematologist from H. Lee Moffit Cancer Center, discusses current thinking on MDS/MPN overlap disorders and myelofibrosis.

Dr. Timothy Olson, a pediatric hematologist at Children's Hospital of Philadelphia, discusses the most current thinking on treatment of children with aplastic anemia. This video was recorded at the Aplastic Anemia and MDS International Foundation's Scientific Symposium in March, 2018.

Dr. Lucy Godley, University of Chicago, and Dr. Luca Malcovati, University of Pavia, discuss the highlights of their session on Genetics and Genomics of Bone Marrow Failure at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Dr. David Margolis, Medical College of Wisconsin, and Dr. Danielle Townsley, MedImmune, discuss the highlights of their session on Treatment Options for Aplastic Anemia at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018. Topics include precision medicine, eltrombopag, and bone marrow transplantation.

Dr. Antonio Risitano, University of Naples and Dr. Regis Peffault DeLatour, Hospital de St. Louis, discuss recent research on treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Dr. Timothy Graubert, Massachusetts General Hospital and Dr. Stephanie Halene, Yale University School of Medicine discuss the highlights of their session on the Biology of Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Dr. Toyosi Odenike, University of Chicago and Dr. Eric Padron, H. Lee Moffitt Cancer Center, discuss the highlights of their session on Non-Transplant Treatments for Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.

Focusing on the "and" instead of the rest

“Sometimes ‘a new normal’ seems to have a bad connotation,” said Nicole Lise Feingold, director of Patient Services at the Pancreatic Cancer Action Network (PanCAN).

Having cancer can change the word "normal" forever.

Women are more likely to die from bladder cancer earlier on after diagnosis, according to recent study findings published in the European Journal of Cancer. However, after that time frame the risk of death is higher for men.

Nothing is worse than the long-term effects like chemo fog and going deaf. I do think that we need to report these medications and hope research will try to develop treatments with fewer side effects.

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

This week, I celebrated eight years since diagnosis. It brought back a lot of thoughts and feelings.

"The objective is to equip the research and drug development communities with the data needed to move better MPN treatments, and potentially, cures, through the discovery pipeline more quickly."

Today's approval of Tibsovo, along with the diagnostic tool to determine who should get it, brings a new type of treatment for patients with acute myeloid leukemia.